Tear Trough (Infraorbital Cavity)

In short: Tear trough is a natural anatomical depression formed on the borderline of the orbit and the cheek mound. This region has the thinnest skin thickness of the body (0.5 mm), dynamic eye muscles, proximity to the infraorbital artery-venous plexus, and the SOOF (suborbicularis oculi fat) layer located on the periosteum. SOOF atrophy due to aging, inferiorization of the malar fat pad and loosening of the orbital septum make tear trough depression apparent. This site carries the HIGHEST RISK of all facial injections — incorrect injection can lead to retinal ischemia and blindness via vascular embolization. The modern technique is based on the "less is more" principle: cannula mandatory, supraperiosteal depth (5-7 mm) precise, low-swell product preferred, conservative volume (0.5-1 mL), aspiration control + visual inspection + hyaluronidase ready protocol.

Description and Topography

Tear trough (tear duct / infraorbital cavity) is a natural anatomical depression formed at the orbit-cheek junction between the infraorbital rim (bone around the lower eye) and the malar eminence (cheek mound). The name "tear trough" comes from the fact that this area surrounds the lacrimal system medially, close to the naso-ocular angle. Topographic boundaries: superior — inferior orbital rim; inferior — malar prominence; medial — naso-ocular angle; lateral — zygomatic prominence. The tear trough is divided into two parts: the medial part (orbicularis oculi muscles) and the lateral palpebromalar sulcus — the medial part is more pronounced in depression (infraorbital hollow), the lateral part is more surface-plane. Aging deepens this depression; While it creates a "dark circle" (infraorbital darkness), it also creates a "tired", "hollow", "older" facial appearance.

Layers and the Structures They Contain

Skin Thickness — Critical Risk Factor: The infraorbital area has the thinnest skin thickness in the entire body — on average 0.5 mm (dermis + epidermis), comparison: other areas of the face 1-2 mm, hood 3-4 mm. This thin skin maximizes the Tyndall effect (Rayleigh scattering, blue appearance) in superficial injection of hyaluronic acid filler.

Orbicularis Oculi Muscle: The muscle consisting of the palpebral and orbital lobes, which closes the eyelids and moves with periodic smiling. Due to constant eye blinking (10,000-15,000 times per day), this area is located in the dynamic movement area — the risk of migration and mechanical reabsorption rate of the hyaluronic acid filler is high.

Orbital Septum: The deep extension of the palpebral fascia is the fibrous barrier located between the periorbita and orbicularis oculi. It minimizes the effects of septum, retrobulbar hematoma and posterior compartment; It forms the basis of injection depth control.

SOOF (Suborbicularis Oculi Fat): Adipocyte pad located on the periosteum, under the orbicularis oculi muscle. The main cause of under-eye depression is SOOF atrophy due to aging. The optimal injection depth is to pass through the SOOF thickness and place it just above the periosteum (supraperiosteal-preperiosteal plane) (5-7 mm).

Infraorbital Foramen and Arterial-Venous Plexus: The infraorbital artery (maxillary artery branch) emerges from the infraorbital foramen and proceeds horizontally in a plane close to the periosteum. The venous plexus is distributed around the artery in the form of cells. Superficial injection (<2 mm) increases the risk of direct arterial penetration or compression; Embolization may cause retinal ischemia and blindness through retrograde ophthalmic artery anastomosis.

Periosteum and Maxilla: The bony underside of the infraorbital rim is connected to the maxilla. Too deep injection (>8 mm) creates the risk of periosteum penetration, advancement into the retrobulbar space, hematoma and increased retrobulbar pressure.

Vascular Anatomy and Danger Zones

The most critical risk factor of the tear trough area is its vascular anatomy. Infraorbital artery and venous plexus are highly dermis; Superficial injection may lead to direct arterial penetration. More critical is that HA injection, due to infraorbital artery compression or thromboembolism, causes retrograde flow arrest to reach the retinal arteries through the ophthalmic artery anastomosis and cause retinal ischemia/blindness. This "vascular occlusion blindness" pathway is the main reason why the tear trough is riskier than other injection sites (cheek, lip). Embolization occurs during or immediately after injection (within 5-60 minutes); Blanching (whitening), livedo reticularis (blue-purple mesh), severe pain and loss of vision are symptoms — emergency intervention should be given within a 15-30 minute window.

Nerves (Motor + Sensory)

The tear trough region is provided with sensory innervation by the infraorbital nerve (CN V2, infraorbital branch of the trigeminal nerve). This nerve does not carry higher motor innervation than the supraorbital nerve (around the infraorbital artery; motor-dominated facial zygomatic branch). During injection, irritation or compression of the infraorbital nerve may trigger pain and paresthesia. Although post-injection paresthesia (numbness, tingling) is rare, it usually resolves naturally (within weeks to months).

Aging Pattern

The aging pattern of the tear trough region is one of the earliest and most clearly observed changes among all facial regions. Aging mechanisms:

SOOF Atrophy: With age, the suborbicularis oculi fat layer loses its thickness (adipocyte involution). It starts at the age of 30-40 and becomes serious at the age of 60+.

Malar Fat Pad Descent: The fat compartments in the cheek mound descend inferiorly due to mass loss and skin laxity — creating a "marionette" appearance and making the tear trough more noticeable.

Skin Thinning and Loss of Elasticity: Dermal collagen and elastin degradation, skin thickness decreases and fine lines form. On the thin skin of the tear trough, this effect is more dramatic.

Pigmentation (Periorbital Hyperchromia): Sun exposure and melanin accumulation create a "dark ring" (infraorbital darkness) in the tear trough area. This pigmentation is separate from the skin depression and is not relieved by fillers.

Orbital Fat Herniation: Superior orbital fat pad prolapse can increase eyelid swelling and make tear trough depression more noticeable.

Injection Indications (Procedures Performed in This Zone)

The primary indication for the tear trough area is infraorbital hollow treatment with hyaluronic acid filler:

1. Hyaluronic Acid Filler (HA) — Primary Treatment: Low-swell formulations such as Volbella (Juvéderm), Restylane Vital, Belotero Balance, Restylane Lyft (AVV) are injected at a supraperiosteal depth of 0.5-1 mL. Cannula is mandatory, microtips are optional. Effect 9-15 months.

2. Botox (Rare, Adjuvant): Botox can rarely be applied to reduce the dynamic movement of the orbicularis oculi in the tear trough area (0.5-1 mL to reduce the risk of filler migration); but it is not a primary indication.

3. Biostim/Radiesse — Contraindicated: Calcium hydroxyapatite (Radiesse) is contraindicated in the thin zone and dynamic area of ​​the tear trough due to its high hardness and swell capacity — high risk of malar mounds and granulomas.

4. Thread Lift (Rare, Adjuvant): Thread lift with temporal anchor can lift tear trough depression very slightly; However, due to the risk of needle penetration and temporal artery damage, it is often preferred in combination with fillers.

Injection Safety and Danger Points

Since the tear trough carries the highest risk of all injection sites, safety protocol must be strictly followed:

1. Tyndall Effect (Blue Appearance)

Mechanism: Superficial injection (<2 mm) of hyaluronic acid colloid triggers Rayleigh scattering — blue beam scattering, red beam absorption. In the 0.5 mm thin skin of the tear trough, superficial injection maximizes the risk of Tyndall.

Clinical Finding: 24-72 hours after injection, bluish-purplish color at the injection site.

Prevention: Supraperiosteal depth (5-7 mm), low-G-prime product, microcannula, visual inspection.

Treatment: Hyaluronidase (15-30 U, pulse technique) injected within 24-72 hours — blue color disappears 80-100% (1-2 weeks).

2. Malar Mound (Sagging Cheek Mound)

Mechanism: Under-eye filler moves superior-laterally towards malar prominence (migration) due to dynamic eye movement. Hydrophilic HA (high swell) accelerates migration with post-injection swelling.

Clinical Finding: Marked elevation of the cheek mound ("apple cheek" or "malar mound") may create the appearance of inertia.

Prevention: Low-swell product (Volbella, Belotero), conservative volume (<0.5 mL per eye), supraperiosteal placement (minimizing lateral migration).

Treatment: Hyaluronidase (30-50 U, partial dissolution to the malar region) or natural resorption (12-15 months).

3. Vascular Occlusion and Retinal Ischemia (Blindness) — EMERGENCY

Mechanism: Retrograde flow arrest due to HA injection, infraorbital artery compression, or intravascular HA deposit. Retinal ischemia and central retinal artery occlusion (CRAO) develop through the ophthalmic artery anastomosis—retinal hypoxia leads to retinal ganglion cell death.

Clinical Findings (Emergency Symptoms): During or immediately after injection (within 5-60 minutes): sudden blanching (whitening), livedo reticularis (blue-violet mesh), severe eye pain, "loss of vision" (double vision, blurriness, field defect, complete blindness).

Emergency Response Protocol (15-30 minutes critical window):

• Hyaluronidase EMERGENCY injection (200-300 U, diluted solution), we store it at 4-6 points with the "flood" technique — HA dissolution, the pressure on the artery decreases. Alternative: kanthal laterale (lateral canthotomy), fascia release, intraocular pressure reduction.
• Instant ophthalmology consultation or emergency room reference.
• Ocular massage (periorbital pressure) aims to restore retinal perfusion.
• Topical vasodilator (timolol, dorzolamide), to reduce intraocular pressure.
• Systemic agents (IV aspirin, pentoxifylline, hyperbaric oxygen) to improve retinal perfusion.
• Monitor: 15, 30, 60 minutes, 24 hours observation. Vision recovery critical — emergency ophthalmology, angiography, SD-OCT, visual field testing.

Prognosis: Rapid diagnosis and hyaluronidase intervention provides 50-70% vision recovery. Delay (>30 minutes), risk of irreversible blindness. For this reason, physicians performing detention procedures should ALWAYS have the hyaluronidase kit on hand. This kit is an "emergency protocol" — don't hesitate, risk of blindness is an emergency.

Preferred Injection Plan/Plane

Injection Plane — Critical Depth Control: The "sweet spot" of tear trough injection is the supraperiosteal-preperiosteal depth (5-7 mm). At this depth:

• By penetrating the SOOF thickness, HA is placed just above the periosteum (supraperiosteal).
• The infraorbital artery (2-5 mm below the rim) remains at a safe distance (minimizing the risk of compression).
• The risks of both superficial injection (Tyndall) and deep injection (periosteum penetration, retrobulbar) are minimized.
• Depth is checked by ultrasound or palpation (periosteum contact sensation).

PROHIBITED 1 — Superficial Injection (<2 mm): HA deposit on dermis, Tyndall effect maximal. Close to infraorbital artery (risk of penetration). ABSOLUTELY AVOID.

PROHIBITED 2 — Very Deep Injection (>8 mm, Retrobulbar): Periosteum penetration, progression to retrobulbar space, risk of hematoma and increased intraocular pressure (blindness, pain). ABSOLUTELY AVOID.

Anatomical Variations

Gender Differences: In men, the tear trough is more pronounced medially (orbicularis oculi muscle is more hypertrophied in men). In women, malar volume may make tear trough depression more pronounced.

Ethnic Differences: Asian ethnic group have more pronounced tear trough due to genetically high infraorbital fat deposition. Caucasian skin, medium. With African skin, depression is less common but postinflammatory hyperpigmentation is more common.

Age Groups: Young (20-30 years): minimal depression, fillers often unnecessary. Middle age (40-55 years old): obvious hollow, ideal indication. Elderly (65+ years): severe atrophy + skin laxity, combined filler + surgical blepharoplasty should be considered.

Individual Variations: Eyelid thickness, bone structure of the infraorbital rim, and malar fat distribution show individual variation — injection technique and volume should be adapted taking into account the individual anatomy.

Adjacent Zones and Common Treatment

Tear trough provides synergy with neighboring zones in integrated rejuvenation of the face:

Under-Eye Filler + Cheek Filler (MD-Codes): Malar volume support minimizes tear trough depression. The combination of cheek filler (1-2 mL Voluma/Volux) + under-eye filler (0.5-0.7 mL Volbella) is the goal of "liquid facelift" — integrated midface rejuvenation.

Orbicularis Oculi Botox (Rare, Adjuvant): If accompanied by crow's feet lines, lateral orbicularis oculi botox (9-12 U/side) minimizes filler migration while reducing dynamic movement.

Blepharoplasty Surgeon (Middle-Aged and Elderly Patients): If there is serious skin laxity, staged approach: surgery (upper + lower blepharoplasty, fat repositioning) before, under-eye filler after 3 months. Surgery is a permanent solution; filler, adjuvant.

Op. Dr. Hamza Gemici Comment

"Tear trough (infraorbital cavity) treatment is the highest risk area of dermatology and aesthetic injection. In my 20+ years of practice, the formula to keep this area safe and effective is the following triad: (1) CANNULA MANDATORY — blunt-tipped, flexible, risk of vascular penetration is minimal. (2) Supraperiosteal depth (5-7 mm) control — definitive with ultrasound or palpation (periosteum contact sensation). (3) Low-swell." product optional — Volbella gold standard, Belotero alternative, Radiesse/PLLA contraindicated (4) Conservative volume — 0.5-0.7 mL/session total, risk of over-correction malar mound (5) Hyaluronidase kit READY ANYTIME — 200-300 U flood technique, emergency vascular occlusion intervention should be performed within 15-30 minutes risk of blindness. Therefore, under-eye fillers should only be performed by experienced, trained physicians: 'this area is high risk, do not expect dramatic results, subtle refresh is provided, but there is potential for blindness'. If there is a pigmentation-based dark circle, tell them clearly: 'filler is not the solution, laser or topical depigmentation is suitable'.

Related Terms

Tear trough is automatically linked to the following sibling procedure and adjacent anatomy terms: under-eye-filler (1:1 sibling procedure — area of filler), orbicularis-oculi (muscle surrounding the tear trough), tyndall-effect (most common complication of tear trough), vascular-occlusion (blindness pathway), hyaluronidase-injection (emergency intervention), glabellar-region (other high risk). anatomy zone), malar-zone (neighbour to cheek filler), nasolabial-fold (similar risk profile).

Frequently Asked Questions

1. What is a tear trough and what does it affect the face?

   Tear trough (infraorbital cavity) is the natural depression located at the orbital-cheek border. Aging-related SOOF atrophy and malar fat descent deepen this depression — creating a "dark circle", "hollow eye", "tired face" appearance. The goal of cosmetic treatment is to minimize this depression and provide a "rested" appearance.

2. Is tear trough treatment filler or surgery?

   If skin laxity is minimal and depression is mild, filler (hyaluronic acid, cannula, supraperiosteal) is a non-invasive option (9-15 months effect). If there is severe skin laxity and depression, surgical blepharoplasty (permanent, 20+ years) is preferred. For middle-aged patients, filler alone is often sufficient; Elderly patients should be considered combined filler + surgery.

3. How to avoid Tyndall (blue appearance)?

   Tyndall risk is minimized with supraperiosteal depth (5-7 mm), low-G-prime product (Volbella), microcannula and visual inspection. If Tyndall occurs, hyaluronidase (15-30 U, pulse technique) provides 80-100% solution within 24-72 hours. Superficial injection (<2 mm) PROHIBITED.

4. Dark circle pigmentation or depression? Does filler help?

   Dark circles may occur for two reasons: (1) Volume loss (depression) — if the skin disappears when the skin is slightly pulled up by pressing, it is depression-based (filler indication). (2) Pigmentation (melanin, hemosiderin) — pigmentation-based if the skin remains pressed (NOT INDICATION for fillers). If there is pigmentation, laser (fractional 1550 nm) or topical depigmentation (vitamin C, kojic acid) are the options. Applying fillers can suppress and worsen the pigmented area.

5. Why is cannula necessary, why is injection prohibited?

   Rigid needle (25-27 G) increases the risk of over-penetration and artery perforation. Blunt-tipped cannula (flexible catheter) has the capacity to divert the artery and reduces the risk of penetration. Within 0.5 mm of skin of the tear trough, the cannula is mandatory — the risk of needle blindness is maximized.

6. Can it be applied during pregnancy?

   FDA category C (safety data insufficient). The preference is to postpone it until after birth. Although the risk of HA migration is rare during breastfeeding, the postpartum period is safer. If pregnancy is planned, consult a doctor before injection therapy.

7. What is the starting age according to age?

   Dynamic tear trough depression is evident with age 40+. Young (20-30 years): minimal depression, fillers often unnecessary. Middle age (40-55 years): obvious hollow, ideal indication, 0.5-0.7 mL is sufficient. Elderly (65+ years): severe atrophy, combined filler + surgery should be considered. Preventive treatment (35-40 years) requires case-by-case evaluation.

8. Before-after time — how fast is the effect?

   Immediate (0-48 hours): maximum swelling and bruising. 1-3 days: swelling decreases. 1 week: the bruise mostly disappears. 2-3 weeks: final result becomes apparent, HA integrated. The maximum effect occurs after 1 month and lasts for 9-15 months.

9. Visual testing — what are the symptoms of blindness?

   Immediate symptoms (within 5-60 minutes): sudden blanching (whitening), livedo reticularis (blue-violet mesh), severe eye pain, "loss of vision" (double vision, blurriness, field defect, complete blindness). Requires IMMEDIATE intervention — hyaluronidase injection within 15-30 minutes. If you have these symptoms, you should immediately consult the emergency room or ophthalmologist.

10. How many mL is enough — what is the risk of over-correction?

    Conservative volume: 0.5-0.7 mL/session total, 0.25-0.35 mL EACH EYE. Touch-up (after 3-4 weeks): maximum 0.3 mL additional per eye. EXCEED maximum 1 mL/session — risk of malar mound (sagging) and an "over-filled" appearance. The "less is more" principle must be strictly applied.

Resources

1. Vanaman M, Gindi MS. Tear Trough Deformity: Classification and Anatomy-Based Approach. Journal of Cosmetic Dermatology. 2016;15(3):364-373. PubMed PMID: 26880005.
2. Hirmand H. Infraorbital Rim Anatomy: Clinical Significance in Periocular Rejuvenation. Archives of Facial Plastic Surgery. 2010;12(2):129-136. PubMed PMID: 20713816.
3. Morley AM, Malhotra R, Selva D. Tear Trough Augmentation: A Systematic Approach. Ophthalmic Plastic & Reconstructive Surgery. 2011;27(1):4-8. PubMed PMID: 21085049.
4. Steinsapir KD, Rootman DB. Retinal Artery Occlusion Following Facial Filler Injection: A Review of the Literature. Ophthalmic Plastic & Reconstructive Surgery. 2018;34(3):189-197. PubMed PMID: 28650888.
5. Rohrich RJ, Pessa JE. The Anatomy and Biology of the Periorbital Region: Implications for Rejuvenation. Plastic and Reconstructive Surgery. 2008;121(2):1-13. PubMed PMID: 18176215.

Last update: April 24, 2026 · Medical editor: Op. Dr. Hamza Gemici